Form 4: Quest Diagnostics SVP Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, sold 1,975 shares of common stock for $185 per share as part of a pre-arranged 10b5-1 sales plan.
Summary
- Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (DGX), reported a sale of common stock.
- The transaction involved the disposition of 1,975 shares of common stock.
- The shares were sold at a price of $185 per share.
- Following this transaction, Plewman beneficially owns 15,269 shares of common stock directly.
- The sale was executed on August 21, 2025, and was made pursuant to a Rule 10b5-1 sales plan.
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-scheduled insider stock sale under a 10b5-1 plan, which is generally considered a neutral event with no direct positive or negative implications for the company's operational or financial performance.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Quest Diagnostics' future performance or strategic direction.
Industry Context
This filing is a standard disclosure of an insider stock transaction and does not provide information relevant to broader industry trends or competitive landscape analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The reported sale was executed pursuant to a Rule 10b5-1 sales plan, indicating adherence to insider trading policies designed to prevent trading on material non-public information. | 08/21/2025 | Reinforces commitment to corporate governance best practices regarding insider transactions. |
Stakeholder Impact
- Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal impact on shareholder sentiment, as it is pre-scheduled and not indicative of new information.
Key Dates
| Date | Description |
|---|---|
| 08/21/2025 | Date of earliest transaction (sale of common stock) |
| 08/25/2025 | Signature date of the reporting person's attorney-in-fact |
Keywords
Quest Diagnostics, DGX, Insider Trading, Stock Sale, Form 4, Patrick Plewman, 10b5-1 Plan, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.